

Generic Oncology Drugs Market is Projected to Increase at a CAGR of 6.6% Through 2025-2029

The Business Research Company's Generic Oncology Drugs Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, November 24, 2025 /EINPresswire.com/ -- What Is The Projected Market Size & Growth Rate Of The Generic Oncology Drugs Market?



In recent times, the <u>generic oncology drugs market size</u> has seen substantial growth. From 2024 to 2025, the market size is expected to rise from \$27.24 billion to \$28.75 billion, marking a compound annual growth rate (CAGR) of 5.5%. The growth observed in the historic period can be

"

Get 20% Off All Global
Market Reports With Code
ONLINE20 – Stay Ahead Of
Trade Shifts,
Macroeconomic Trends, And
Industry Disruptors"
The Business Research
Company

ascribed to factors such as the expiry of patents, cost containment in healthcare, rising incidence of cancer, health insurance coverage, and the prescribing practices of physicians.

The generic oncology drugs market is set for robust expansion in the coming years, projected to reach \$37.08 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 6.6%. The predicted growth during the forecast period can be linked to the approval of biosimilars, heightened competition, the rise of telemedicine and

remote care, personalized treatment models, and pricing pressures. Noteworthy trends during the forecast period are expected to include enhanced pharmacovigilance, regulatory simplification, a shift towards combination therapy, precision in generic oncology medications, and broader market accessibility.

Download a free sample of the generic oncology drugs market report: https://www.thebusinessresearchcompany.com/sample.aspx?id=12174&type=smp

What Is The Crucial Factor Driving The Global Generic Oncology Drugs Market? The surge in individuals affected by cancer is anticipated to boost the expansion of the generic oncology drugs market. Cancer, a disease marked by unregulated cell proliferation affecting different organs, is responsible for considerable morbidity and mortality around the world. Generic oncology drugs, being cost-effective, play a paramount role in the treatment of cancer by enhancing the availability of vital therapies, fostering market competition, and mitigating healthcare expenses. For example, the National Cancer Institute (NCI), a governmental agency in the United States, reported in January 2022 that approximately 5.4% of the population, equating to 18.1 million people, were cancer survivors. Additionally, it recorded 623,405 individuals living with metastatic breast, prostate, lung, colorectal, bladder cancer, or metastatic melanoma in 2022, a figure predicted to increase to 693,452 by 2025. Consequently, the substantial surge in cancer patients is instigating the growth of the generic oncology drugs market.

Who Are The Emerging Players In The Generic Oncology Drugs Market? Major players in the Generic Oncology Drugs include:

- Pfizer Inc.
- AbbVie
- Novartis AG
- Bristol-Myers Squibb Company
- AstraZeneca Plc
- Abbott Laboratories
- Fresenius Kabi AG
- GlaxoSmithKline PLC
- Eli Lilly and Company
- · Merck & Co. Inc.

What Are The Key Trends Shaping The Generic Oncology Drugs Industry? A significant trend making waves in the generic oncology drugs market is the creation of innovative formulations. Major corporations in this sector are prioritizing the development of advanced drug delivery systems, modified-release formulations, and varying dosage forms to enhance patient adherence and solidify their market standing. An example of this trend occurred in January 2023, when generic drug specialist MSN Laboratories Private Limited, based in India, unveiled Palborest, the global premier generic Palbociclib tablet for treating advanced breast cancer. This cost-efficient tablet grants similar performance as the original, while ensuring bioequivalence. An added benefit of the tablet form is flexibility, as it can be consumed with or without meals and may be co-administered with proton pump inhibitors or antacids. Plus, the tablet formulation is devoid of lactose and gelatin, which further enhances the drug's effectiveness.

What Segments Are Covered In The Generic Oncology Drugs Market Report? The generic oncology drugs market covered in this report is segmented –

1) By Molecule Type: Large Molecule, Small Molecule

- 2) By Route Of Administration: Oral, Parenteral
- 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Managed Care Institutions

Subsegments:

- 1) By Large Molecule: Monoclonal Antibodies, Biologics, Biosimilars
- 2) By Small Molecule: Chemotherapeutics, Targeted Therapy Agents, Hormonal Therapy Drugs

View the full generic oncology drugs market report:

https://www.thebusinessresearchcompany.com/report/generic-oncology-drugs-global-market-report

Which Region Is Projected To Hold The Largest Market Share In The Global Generic Oncology Drugs Market?

In 2024, the generic oncology drugs market was dominated by North America, leading as the largest region. The growth outlook for this market is projected in the report covering regions including Asia-Pacific, Western Europe, Eastern Europe, South America, Middle East, and Africa.

Browse Through More Reports Similar to the Global Generic Oncology Drugs Market 2025, By The Business Research Company

Transportation Management Systems Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/transportation-management-systems-global-market-report

Serviced Office Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/serviced-office-global-market-report

Smart Transportation Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/smart-transportation-global-market-report

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company - <u>www.thebusinessresearchcompany.com</u>

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

This press release can be viewed online at: https://www.einpresswire.com/article/869164577

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.